You may leave me a review on these links:

Dr Catherine Lucas

  • Nuclear Medicine Physician
  • Spoken languages English


Catherine developed her interest in theranostics during her advanced training in nuclear medicine at the Royal Brisbane and Women’s Hospital.

Clinical interests

Dr Lucas is also interested in clinical pharmacology

Professional Memberships

  • ANZSNM – Australian and New Zealand Society of Nuclear Medicine
  • ANZUP – Australian and New Zealand Urogenital and Prostate Cancer Trials Group
  • ASCEPT – Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists
  • BPS – British Pharmacological Society
  • IATDMCT – International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Publications & Affiliations

  • Patel J, Lucas CJ, Margalit M, Martin JH. Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. Journal of Pain and Palliative Care Pharmacotherapy. 2018;32(2-3):116-123.
  • Ryan J, Patel J, Lucas CJ, Martin JH. Optimal cancer drug dosing in adolescents: new issues and the old unaddressed ones. Internal Medicine Journal 2018;48:1023-1027.
  • Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH. Cannabinoid disposition after human intraperitoneal use: an insight into intraperitoneal pharmacokinetic properties in metastatic cancer. Clinical Therapeutics 2018;40(9):1442-1447.
  • Lucas C, Martin J. Pharmacokinetic-guided Dosing of New Oral Cancer Agents. The Journal of Clinical Pharmacology 2017;57(S10):S78-S98.
  • Lucas C, Goodman S, Smith J, Burge M, Wyld D, Ravi Kumar A. Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate. Poster presented at: 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; 2016 Mar 9-11; Barcelona, Spain.